The Clinical Trials Informatics and Biostatistics Core (CTIBC) serves as a centralized resource to the? investigators of the Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies Program Project? Grant (PPG), providing biostatistical expertise, clinical research management and informatics resources to all? projects. The CTIBC includes 2 Core Co-Directors, 2 Senior Biostatisticians, 2 Masters Biostatisticians, a? Clinical Trials Administrator, 5 Clinical Research Associates (CRAs), Quality Assurance (QA) and Data? Operation Sections, data entry, and the Phoenix BMT Coordinator. The CTIBC provides study design, sample? size projections, analytic planning, statistical programming, analysis of study results, and collaboration in? writing abstracts and peer-review publications. Statistical analyses are performed using the SAS and S-PLUS? software packages, and specialty software. The CTIBC provides coordination of multi-centered studies,? including documentation of site IRB approval, common Case Report Forms (CRFs), staff training, verification? of subject eligibility, central patient registration, data collection, expectation and quality checking, and? centralized data analyses. A centralized clinical trials database system (BITS) was developed in-house and? has been in continual use for the past 15 years. BITS contains data on all bone marrow transplant recipients to? date, including the data collected by the Long Term Follow-up Core (Core C). The CTIBC has developed? customized data collection instruments specific to the patient populations under study, using a modular forms? design approach and implemented via scannable forms. The CRAs provide protocol management and data? collection for the clinical studies, and the QA team conducts training, review of data, and audits of in-house? protocols. Additional support is provided to the PPG by members of the Division of Information Sciences (DIS)? within which the CTIBC is housed, including expertise from the Department of Biomedical Informatics, at no? additional cost to the grant. This support includes resources and expertise in the creation and maintenance of? information systems and tools, such as integration of electronic medical record data (demographics, lab results,? HLA, vital status) with the BITS database, and automation of CTC grading, in collaboration with PPG? investigators (see Core A). During the last funding period CTIBC members were co-authors of 45 publications? and over 50 abstracts. The CTIBC has been involved in study design for each specific aims of the current? proposal, and will continue to be a critical component to successful conduct of the PPG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA030206-25
Application #
7546255
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2007-04-01
Budget End
2008-03-31
Support Year
25
Fiscal Year
2007
Total Cost
$278,001
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Limaye, Ajit P; La Rosa, Corinna; Longmate, Jeff et al. (2016) Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients. Transplantation 100:210-6
Jonnalagadda, Mahesh; Mardiros, Armen; Urak, Ryan et al. (2015) Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 23:757-68
Wang, Xiuli; Wong, ChingLam W; Urak, Ryan et al. (2015) CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. Clin Cancer Res 21:2993-3002
Mardiros, Armen; Forman, Stephen J; Budde, Lihua E (2015) T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Curr Opin Hematol 22:484-8
Caruso, Hillary G; Hurton, Lenka V; Najjar, Amer et al. (2015) Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Res 75:3505-18
Israyelyan, A; Goldstein, L; Tsai, W et al. (2015) Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant 50:26-33
Wussow, Felix; Chiuppesi, Flavia; Martinez, Joy et al. (2014) Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. PLoS Pathog 10:e1004524
Rushworth, David; Jena, Bipulendu; Olivares, Simon et al. (2014) Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity. J Immunother 37:204-13
Jena, Bipulendu; Moyes, Judy S; Huls, Helen et al. (2014) Driving CAR-based T-cell therapy to success. Curr Hematol Malig Rep 9:50-6
Singh, Harjeet; Huls, Helen; Kebriaei, Partow et al. (2014) A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev 257:181-90

Showing the most recent 10 out of 364 publications